Summary
GlobalData, the industry analysis specialist's new report on the pharmaceutical and healthcare sector, "Type 2 Diabetes-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
-Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11β HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1β antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor.
-Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co., Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 2 diabetes market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global type 2 diabetes market landscape? -Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Type-2 Diabetes Therapeutics Market: Market Characterization 6
2.1 Overview 6
2.2 Type-2 Diabetes Market Size 6
2.3 Type-2 Diabetes Market Forecast and CAGR 7
2.4 Drivers and Barriers for Type-2 Diabetes Market 7
2.4.1 Drivers for Type-2 Diabetes Market 8
2.4.2 Restraints for Type-2 Diabetes Market 8
2.5 Opportunity and Unmet Need 9
2.5.1 Unmet Needs 9
2.5.2 Impact Analysis of Unmet Needs 9
2.6 Key Takeaway 11
3 Type-2 Diabetes Therapeutics Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Marketed Products in the Type-2 Diabetes Market 13
3.3.1 Actos (pioglitazone) 13
3.3.2 Avandia (rosiglitazone) 14
3.3.3 Januvia (sitagliptin) 15
3.3.4 Starlix (nateglinide) 16
3.3.5 Byetta (exenatide) 17
3.3.6 Lantus (insulin glargine) 18
3.3.7 Levemir (insulin detemir) 19
3.4 Key Takeaway 19
4 Type-2 Diabetes Therapeutics Market: Pipeline Assessment 20
4.1 Overview 20
4.2 Strategic Pipeline Assessment 20
4.2.1 Technology Trends Analytic Framework 20
4.3 Type-2 Diabetes Therapeutics-Promising Drugs under Clinical Development 22
4.4 Molecule Profile for Promising Drugs under Clinical Development 23
4.4.1 BMS-512148 (dapagliflozin) 23
4.4.2 Victoza 25
4.4.3 D-Tagatose 26
4.4.4 JNJ-28431754 (canagliflozin) 27
4.4.5 MB07803 28
4.5 Type-2 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action 29
4.6 Type-2 Diabetes Pipeline-Pipeline by Clinical Phases of Development 30
4.6.1 Type-2 Diabetes Therapeutics-Regulatory Filing and Phase III Clinical Pipeline 30
4.6.2 Type-2 Diabetes Therapeutics-Phase II Clinical Pipeline 31
4.6.3 Type-2 Diabetes Therapeutics-Phase I Clinical Pipeline 33
4.6.4 Type-2 Diabetes Therapeutics-Preclinical Pipeline 35
4.6.5 Type-2 Diabetes Therapeutics-Discovery Pipeline 35
4.7 Discontinued/Suspended Drugs for Type-2 Diabetes 35
4.8 Key Takeaway 36
5 Type-2 Diabetes Therapeutics Market: Implications for Future Market Competition 37
6 Type-2 Diabetes Therapeutics Market: Future Players in Type-2 Diabetes Market 39
6.1 Introduction 39
6.2 GlaxoSmithKline 39
6.2.1 Company Overview 39
6.2.2 Business Description 40
6.2.3 Type-2 Diabetes Therapeutics Portfolio 40
6.3 Hoffmann-La Roche 41
6.3.1 Company Overview 41
6.3.2 Business Description 41
6.3.3 Type-2 Diabetes Therapeutics Portfolio 42
6.4 Novo Nordisk 42
6.4.1 Overview 42
6.4.2 Type-2 Diabetes Therapeutics Portfolio 43
6.5 Merck & Co. 43
6.5.1 Overview 43
6.5.2 Business Description 44
6.5.3 Type-2 Diabetes Therapeutics Portfolio 44
6.6 Novartis Ag 44
6.6.1 Company Overview 44
6.6.2 Business Description 45
6.6.3 Type-2 Diabetes Therapeutics Portfolio 45
6.7 Sanofi-aventis 46
6.7.1 Company Overview 46
6.7.2 Business Description 46
6.7.3 Type-2 Diabetes Therapeutics Portfolio 47
6.8 Eli Lilly & Company 47
6.8.1 Overview 47
6.8.2 Type-2 Diabetes Therapeutics Portfolio 48
7 Type-2 Diabetes Therapeutics Market: Appendix 49
7.1 Definitions 49
7.2 Acronyms 49
7.3 Research Methodology 49
7.3.1 Coverage 50
7.3.2 Secondary Research 50
7.3.3 Forecasting 51
7.3.4 Primary Research 54
7.3.5 Expert Panel validation 54
7.4 Contact Us 54
7.5 Disclaimer 54
7.6 Sources 55
List of Tables
1.1 List of Tables
Table 1: Type-2 Diabetes Therapeutics, Global, Sales Value ($ bn), 2001-2009 7
Table 2: Type-2 Diabetes Therapeutics, Global, Sales Value ($ bn), 2009-2016 7
Table 3: Type-2 Diabetes Market, Global, Most Promising Drugs Under Clinical Development, December 2009 22
Table 4: Type-2 Diabetes Therapeutics, Global, Regulatory Approval and Phase III Clinical Pipeline, 2009 30
Table 5: Type-2 Diabetes Therapeutics, Global, Phase II Clinical Development, 2009 31
Table 6: Type-2 Diabetes Therapeutics, Global, Phase I Clinical Development, 2009 33
Table 7: Type-2 Diabetes Therapeutics, Global, Preclinical Development, 2009 35
Table 8: Type-2 Diabetes Therapeutics, Global, Discovery Stage, 2009 35
Table 9: Type-2 Diabetes Therapeutics, Global, Discontinued drugs, 2009 35
Table 10: Type-2 Diabetes Therapeutics, Global, GlaxoSmithKline Products in the Market, 2009 40
Table 11: Type-2 Diabetes Therapeutics, Global, GlaxoSmithKline Pipeline Drugs, 2009 40
Table 12: Type-2 Diabetes Therapeutics, Global, Hoffmann-La Roche Pipeline Drugs, 2009 42
Table 13: Type-2 Diabetes Therapeutics, Global, Novo Nordisk Products in the Market, 2009 43
Table 14: Type-2 Diabetes Therapeutics, Global, Novo Nordisk Pipeline Drugs, 2009 43
Table 15: Type-2 Diabetes Therapeutics, Global, Merck & Co. Products in the Market, 2009 44
Table 16: Type-2 Diabetes Therapeutics, Global, Merck & Co. Pipeline Drugs, 2009 44
Table 17: Type-2 Diabetes Therapeutics, Global, Novartis Products in the Market, 2009 45
Table 18: Type-2 Diabetes Therapeutics, Global, Novartis Pipeline Drugs, 2009 46
Table 19: Type-2 Diabetes Therapeutics, Global, Sanofi-aventis Products in the Market, 2009 47
Table 20: Type-2 Diabetes Therapeutics, Global, Sanofi-aventis Pipeline Drugs, 2009 47
Table 21: Type-2 Diabetes Therapeutics, Global, Eli Lilly & Co. Products in the Market, 2009 48
Table 22: Type-2 Diabetes Therapeutics, Global, Eli Lilly & Co. Pipeline Drugs, 2009 48
List of Figures
1.2 List of Figures
Figure 1: Type-2 Diabetes Therapeutics, Global, Sales Value ($ bn), 2001-2016 7
Figure 2: Type-2 Diabetes Therapeutics, Global, Market Opportunity and Unmet Needs, 2009 10
Figure 3: Type-2 Diabetes Therapeutics, Global, Strategic Competitor Assessment of Major Marketed Products, 2009 13
Figure 4: Type-2 Diabetes Therapeutics, Global, Pipeline, Technology Trends Analytic Framework, 2009 20
Figure 5: Type-2 Diabetes Therapeutics, Global, Pipeline, Description of Technology Trends Analytic Framework, 2009 21
Figure 6: Type-2 Diabetes Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009 29
Figure 7: Type-2 Diabetes Therapeutics, Global, Pipeline by Phase of Clinical Development, 2009 30
Figure 8: Implications for Future Market Competition in the Type-2 Diabetes Market, 2009 37
Figure 9: Type-2 Diabetes Therapeutics Market, Global, Clinical Pipeline by Company, 2009 39
Figure 10: GlobalData Methodology 50
Figure 11: GlobalData Market Forecasting Model 53
